Genetic and Protein Biomarkers for Prostate Cancer — Coverage Criteria
Defines coverage, prior authorization, and medical necessity criteria for genetic and protein biomarker tests used to aid diagnosis and risk assessment of prostate cancer for Medicare Advantage and Commercial members of Blue Cross Blue Shield Rhode Island.
No material clinical or coverage changes in this revision.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.